![]() The alliance will utilize Atreca’s proprietary discovery platform to generate the sequences of antibodies made by particular B cells found in blood obtained from acutely infected COVID-19 patients. IgA and IgM antibodies also have the inherent property of active transport from the blood stream to mucosal surfaces, such as in the lung, which may provide a therapeutic advantage for respiratory diseases such as COVID-19. This greater binding power could potentially result in better activity against a broader range of variants of the virus which causes COVID-19, as compared to traditional IgG antibodies. IGM Biosciences engineers IgM and IgA antibodies with greater binding power per antibody, relative to comparable IgG antibodies. Immunoglobulin M (IgM) and immunoglobulin A (IgA) are classes of antibodies naturally produced by the human immune system and are differentiated from immunoglobulin G (IgG) antibodies in part by their greater number of binding domains (IgM: 10, IgA: 4, IgG: 2). Given the urgency of the global COVID-19 pandemic, the parties have agreed to begin work immediately and plan to finalize financial details and other terms in the future. The companies will leverage their combined technology and expertise in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. (Nasdaq: IGMS), today announced their plans to collaborate to help address the COVID-19 pandemic. (Nasdaq: BGNE HKEX: 06160), and IGM Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., CAMBRIDGE, Mass., BEIJING and MOUNTAIN VIEW, Calif., Ap(GLOBE NEWSWIRE) - Atreca, Inc. Therapeutic antibodies to combat ongoing COVID-19 pandemic. ![]() Companies to utilize proprietary platforms to discover, develop, and manufacture potential ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |